Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» anti-PD-L1
anti-PD-L1
Boehringer, BeiGene enter manufacturing pact for PD-1 drug
Boehringer, BeiGene enter manufacturing pact for PD-1 drug
Biopharma Dive
Boehringer Ingelheim
BeiGene
tislelizumab
anti-PD-L1
drug manufacturing
Flag link:
Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?
Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?
Endpoints
Regeneron
Sanofi
anti-PD-L1
cemiplimab
advanced cutaneous squamous cell carcinoma
Flag link:
Pfizer, Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study
Pfizer, Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study
Endpoints
Pfizer
Merck KGaA
Bavencio
anti-PD-L1
gastric cancer
Flag link:
An explosion of PD-1/L1 checkpoint studies is crowding the industry pipeline — and that’s a problem
An explosion of PD-1/L1 checkpoint studies is crowding the industry pipeline — and that’s a problem
Endpoints
anti-PD-L1
drug development
Flag link:
Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance
Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance
Endpoints
Sanofi
Regeneron
fast track
breakthrough status
cemiplimab
anti-PD-L1
Flag link:
Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table
Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table
Endpoints
Celgene
anti-PD-L1
BeiGene
Flag link:
Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?
Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?
Endpoints
Merck
anti-PD-L1
Keytruda
MK-1308
Bristol-Myers Squibb
Flag link:
AstraZeneca delays PD-L1 data in rejig of phase 3 program
AstraZeneca delays PD-L1 data in rejig of phase 3 program
Fierce Biotech
AstraZeneca
anti-PD-L1
clinical trials
tremelimumab
durvalumab
Flag link:
Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?
Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?
Endpoints
AstraZeneca
durvalumab
anti-PD-L1
bladder cancer
Flag link:
FDA Grants Merck Priority Review for Keytruda Drug (MRK)
FDA Grants Merck Priority Review for Keytruda Drug (MRK)
Investopedia
FDA
priority review
Keytruda
Merck
non-small cell lung cancer
anti-PD-L1
Flag link:
Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
Market Realist
AstraZeneca
anti-PD-L1
durvalumab
Opdivo
Keytruda
Tecentriq
Bristol-Myers Squibb
Roche
Merck
Flag link:
New anti-PD1 drugs overpriced, ICER says
New anti-PD1 drugs overpriced, ICER says
BioPharma Dive
drug pricing
ICER
anti-PD-L1
Opdivo
Keytruda
Bristol-Myers Squibb
Merck
Flag link:
Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data
Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data
Seeking Alpha
Amgen
biosimilars
AstraZeneca
anti-PD-L1
ABP 501
Humira
durvalumab
Flag link:
AstraZeneca wins FDA breakthrough status for key cancer drug
AstraZeneca wins FDA breakthrough status for key cancer drug
Yahoo/Reuters
AstraZeneca
FDA
breakthrough status
durvalumab
bladder cancer
anti-PD-L1
Flag link:
Pfizer, Merck KGaA launch two more PhIII trials for avelumab
Pfizer, Merck KGaA launch two more PhIII trials for avelumab
Fierce Biotech
Pfizer
Merck KGaA
avelumab
ovarian cancer
anti-PD-L1
Flag link:
Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer
Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer
Fierce Biotech
Genentech
anti-PD-L1
atezolizumab
ASCO
Flag link:
AstraZeneca and Lilly to test new cancer drug combination
AstraZeneca and Lilly to test new cancer drug combination
Yahoo/Reuters
Eli Lilly
AstraZeneca
MEDI4736
Cyramza
anti-PD-L1
Flag link:
FDA Grants Breakthrough Therapy Designation To Genetech’s Cancer Immunotherapy
FDA Grants Breakthrough Therapy Designation To Genetech’s Cancer Immunotherapy
Bidness Etc.
FDA
breakthrough therapies
Genentech
anti-PD-L1
MPDL3280A
non-small cell lung cancer
Flag link:
Merck KGaA seeks partner for immuno-oncology drug by year-end
Merck KGaA seeks partner for immuno-oncology drug by year-end
Yahoo/Reuters
Merck KGaA
immuno-oncology
anti-PD-L1
Flag link:
Pharma’s Huge Bet on Immunotherapies
Pharma’s Huge Bet on Immunotherapies
Motley Fool
immunotherapy
anti-PD-1 immunotherapy
anti-PD-L1
MK-3475
Merck
nivolumab
Roche
Bristol-Myers Squibb
Flag link:
Pages
1
2
next ›
last »